Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 5, 2013

BioReliance Opens Clearance Services Laboratories in US

BioReliance opens Clearance Services Laboratories in Maryland for downstream bioprocessing studies.

BioReliance

, SAFC’s biologics and early-development services business, has opened a Clearance Services facility in Rockville, MD.

This facility, commissioned on Aug. 1, 2013, doubles the amount of space available to clients to conduct downstream bioprocessing studies.

The Rockville facility features four clearance suites with modular layouts that allow for customized laboratory setups. The investment completes BioReliance’s global facility upgrade plan. The Stirling, Scotland, Clearance Services laboratories were renovated and expanded in 2011.

Source:

BioReliance


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.